Compare CAVA Group Inc (CAVA) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CAVA Group Inc vs Merck & Co., Inc. — how do they compare? CAVA Group Inc trades at $68.48 (market cap $7.08B), while Merck & Co., Inc. trades at $130.42 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 45.4× CAVA Group Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while CAVA Group Inc pays none. Which is the better fit depends on your goals.
| CAVA | MRK | |
|---|---|---|
Market Cap | $7.08B | $321.77B |
Sector | Consumer Cyclical | Health |
52-Week High | $97.39 | $131.84 |
52-Week Low | $43.59 | $77.60 |
Enterprise Value | $7.23B | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CAVA trades at $62.42, up 0.31% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong revenue growth to $1.18B in 2025 and has beaten earnings estimates in two of the last three quarters. Recent news highlights anticipation for the Q2 2026 earnings report, with analysts citing strong traffic and expansion as positive catalysts.
Wall Street maintains a bullish outlook with a consensus price target of $91.00, though high valuation multiples and recent net cash outflows pose risks. The stock's investment case hinges on continued execution of its growth strategy amid competitive industry pressures.
Merck (MRK) trades at $130.90, up 1.81% on the day, with a bullish technical outlook and strong institutional support. Recent earnings beats in Q4 2025 and Q1-Q2 2026, alongside a 28.07% net income margin in 2025, highlight operational strength. The acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, though a high P/E of 104.74 signals premium valuation. Cash flow remains positive at $1.37B in 2025, but investing outflows have increased.
The stock offers growth potential from pipeline expansion and analyst consensus targeting $140.36, but risks include elevated debt-to-asset ratios (36.06% in 2025) and competitive pressures. Investors should weigh robust profitability against valuation concerns and macroeconomic headwinds affecting the pharma sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CAVA Group Inc
CAVA is a Mediterranean fast-casual restaurant brand in the US. It offers customizable bowls, salads, and pitas featuring healthy ingredients, while also selling its signature dips and dressings in grocery stores.
Read more on CAVA →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
